Dr. Golding completed his medical and PhD training at Johns Hopkins University School of Medicine in 2002. He then completed his internal medicine residency training at Johns Hopkins Bayview Medical Center followed by Rheumatology Fellowship at Johns Hopkins, which ended in 2009. From 2009 to 2012 Dr. Golding was an IRTA post-doctoral fellow in the lab of Dr. Ethan Shevach in the Laboratory of Immunology at the NIAID, NIH. During that time he served for one year as a post-doc member of the NIH Immunology Interest Group. Currently, Dr. Golding is a faculty member in the Department of Medicine, Division of Rheumatology and Clinical Immunology and he is also a faculty member in the Department of Molecular Microbiology and Immunology. He has a joint appointment at the Baltimore VA, where he see patients in the VA arthritis clinic.
Dr. Golding completed his PhD (Johns Hopkins Graduate Program in Cellular and Molecular Medicine) under the mentorship of Dr. Mark Schlissel. His thesis focused on the regulation of V(D)J rearrangement by chromatin accessibility. The project showed that the basic structure of chromatin, the nucleosome, can inhibit cutting of the recombination signal sequence by the RAG1/2 proteins. During Dr. Golding's rheumatology fellowship, he switched his focus to the study of human regulatory T cells. He studied the affects of an inflammatory environment in systemic lupus erythematosus (SLE) on Tregs and showed that Type I IFN can suppress normal Treg expansion. Dr. Golding then pursued additional training in Treg biology in the lab of Dr. Ethan Shevach at the NIAID. He completed projects looking at the TCR repertoire of human Tregs with deep sequencing of the TCR CDR3 (manuscript in preparation). In addition, he applied an improved method for identifying human Tregs, which combines Helios with FoxP3, to the study of Tregs in SLE (manuscript accepted, in press Arthritis and Rheumatism). Dr. Golding currently has a 4 year Career Development Award from the VA to study human Tregs in patients with rheumatologic disease. He is hoping to continue to improve our understanding of the role Tregs have in controlling autoimmune disease. In addition, he applied an improved new B-cell derived autoantigens in SLE (Arthritis and Rheumatism, Nov. 2013). Dr. Golding currently has a 4 year Career Development Award funded by the Veterans Administration to study human Tregs in patients with rheumatologic disease. In addition, he has been awarded an American College of Rheumatology/Rheumatology Rsesearch Foundation Career Development Bridge Funding Award (2014-2016) to expand work on the role of human Tregs in suppressing auto-reactive B cells in SLE. Dr. Golding's goal is to improve our understanding.
Internal Medicine & Rheumatology (both board-certified)
Lab Techniques and Equipment:
Cellular Immunology, Flow Cytometry, Tissue culture differentiation of helper T cells, Isolation of lymphocytes with magnetic bead separation, Treg suppression assays, Western Blotting/Protein Biology with patient sera.
Equipment includes an AutoMacsPro from Miltenyi Biotec, standard western blot apparatus, Accuri flow cytometer (property of Baltimore VA Core Facility), and Flow cytometry antibodies; we also have access to rheumatology patient samples through an IRB-approved study in the VA/University of Maryland.